The product was distributed in the United States from August 2016 through September 2016.
“Anyone with an existing inventory of the recalled lot should stop use and distribution and quarantine the product immediately,” said the FDA in the release. “Inform healthcare professionals in your organization of this recall. If you have further distributed the recalled product, please notify any accounts or additional locations which may have received the recalled product from you.”
Previous research has classified the formation of particulate matter as one of the major quality concerns in the development of biopharmaceutical products. The possible presence of such particles in the Hospira antibiotic could result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and low-level allergic reactions if injected.
Vancomycin hydrochloride is an antibiotic used to treat multiple conditions including serious infections caused by methicillin-resistant staphylococci. No adverse events involving the Hospira antibiotic have been reported.
More articles on supply chain:
Tom Price open to CMS negotiating drug prices
6 quotes from Dr. Joseph Gulfo — Trump’s potential pick for FDA commissioner
3 ways to improve supplier relationships
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.